BNP Paribas Asset Management
ADVM

BNP Paribas Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

BNP Paribas Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-391
Closed -$211K – 1048
2014
Q4 		$211K Buy
+391
New +$151K ﹤0.01% 940

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BNP Paribas Asset Management's ADVM Position: Q1 2015 in Review

BNP Paribas Asset Management sold out of Adverum Biotechnologies (ADVM) in Q1 2015, closing a stake of 391 shares — an estimated $211K sold.

BNP Paribas Asset Management first reported a position in ADVM in Q4 2014 and held it in 1 quarter. The position peaked at $211K in Q4 2014. 113 funds tracked by Wall St. Rank hold ADVM as of Q1 2015.

  • BNP Paribas Asset Management reported no remaining Adverum Biotechnologies position as of Q1 2015 after selling out during the quarter.
  • BNP Paribas Asset Management sold 391 Adverum Biotechnologies shares in Q1 2015, an estimated $211K.
  • BNP Paribas Asset Management first reported a position in Adverum Biotechnologies in Q4 2014 and held it in 1 quarter.
  • BNP Paribas Asset Management's Adverum Biotechnologies position peaked at $211K in Q4 2014.
  • 113 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2015.

Based on BNP Paribas Asset Management's 13F filing for Q1 2015, filed 12 May 2015.